The ultimate goal is to develop a novel generation of treatments and therapeutic targets for obesity and metabolic disorders that would pharmacologically target TFF2 pathways to mimic the antiobesity effects of Tff2 KO (Figure 2). This evidence concerns the gene TFF2 and metabolic disease.